NEO-CAIN CREAM

Product Overview

NEO-CAIN CREAM is a South Korean topical anesthetic cream containing 10.56% lidocaine (105.6 mg/g), marketed by NEOGENESIS Co., Ltd. Available in a 500g jar and a 30g tube, both presentations contain the same active ingredient concentration and are designed to temporarily reduce skin sensitivity through local anesthetic activity.

NEO-CAIN CREAM is commercially positioned for professional dermatological and medical aesthetic settings where topical anesthesia may be appropriate. Its lidocaine-based formulation temporarily reduces the transmission of sensory nerve signals associated with pain.

The 500g jar provides a larger professional-use packaging format, while the 30g tube offers a compact alternative. Both presentations are manufactured in South Korea and share the same 10.56% lidocaine specification.

This TEOSQUARE product page covers NEO-CAIN CREAM 500g and NEO-CAIN CREAM 30g, allowing professional buyers to compare their packaging specifications, composition, storage requirements, and safety considerations.

Key Features

• 10.56% Lidocaine: Contains 105.6 mg of lidocaine per gram of cream, providing local anesthetic activity through the temporary inhibition of sensory nerve signaling.
• Two Packaging Options: Available in a 500g professional-size jar and a 30g tube, with the same declared active ingredient concentration.
• Topical Cream Formulation: Supplied as a white to pale-yellow cream intended for external application under appropriate product-specific instructions.
• South Korean Manufacturing: Marketed by NEOGENESIS, which identifies South Korea as the manufacturing origin of its NEO-CAIN anesthetic cream.
• Professional Aesthetic Positioning: Commercially associated with skin-desensitizing applications in dermatology and medical aesthetics, subject to local regulatory authorization and professional assessment.

Composition & Specifications

The principal active ingredient in NEO-CAIN CREAM is lidocaine, an amide-type local anesthetic.

The manufacturer's Korean product literature specifies a lidocaine concentration of 105.6 mg per gram of cream, equivalent to 10.56% by weight.

Published product information also identifies methylparaben as a preservative. The complete quantitative excipient composition should be confirmed against the original product labeling.

Lidocaine — 10.56%

Lidocaine is an amide-type local anesthetic used in pharmaceutical formulations to temporarily reduce sensory nerve conduction.

It acts primarily by blocking voltage-gated sodium channels in nerve cell membranes, preventing the normal propagation of electrical signals.

When used topically under appropriate conditions, lidocaine can reduce the perception of pain and other sensory stimuli in the affected area.

NEO-CAIN CREAM contains 105.6 mg of lidocaine per gram of cream, equivalent to a 10.56% concentration.

This concentration is higher than that found in many conventional low-strength topical lidocaine preparations. The product's suitability, permitted uses, and exposure limits therefore require careful evaluation.

The extent of lidocaine absorption depends on multiple factors, including the formulation, condition of the skin, treated surface area, exposure duration, and use of occlusive coverings.

The 10.56% concentration identifies the amount of lidocaine in the cream. It does not represent a recommended application quantity or establish approval for unrestricted use.

Methylparaben

Methylparaben, also known as methyl hydroxybenzoate, is a preservative commonly used in pharmaceutical and cosmetic formulations.

It helps inhibit the growth of certain microorganisms and contributes to formulation preservation.

Published NEO-CAIN product specifications identify methylparaben at 1.5 mg per gram of cream.

Methylparaben is a supporting formulation ingredient rather than the principal local anesthetic component.

Individuals with relevant hypersensitivity to preservatives or other formulation components may require additional precautions.

Lidocaine-Only Active Ingredient System

NEO-CAIN CREAM is formulated around lidocaine as its declared local anesthetic active ingredient.

It should not be confused with NEO-PRO CREAM, a separate NEOGENESIS product containing both lidocaine and prilocaine.

NEO-PRO is commercially described as a 5% combined local anesthetic formulation containing 2.5% lidocaine and 2.5% prilocaine.

The two products have different active ingredient systems and should not be treated as interchangeable formulations.

The documented active ingredient in NEO-CAIN CREAM is lidocaine. Prilocaine belongs to the separate NEO-PRO product and should not be included in NEO-CAIN's main ingredient description.

How NEO-CAIN CREAM Works

NEO-CAIN CREAM produces temporary local anesthetic effects through the pharmacological action of lidocaine.

Sensory Nerve Transmission

Sensory nerves transmit information through electrical impulses known as action potentials.

These electrical signals depend on the movement of sodium ions through voltage-gated sodium channels in nerve cell membranes.

When sensory nerve endings are stimulated, the resulting electrical impulses carry information toward the central nervous system.

Voltage-Gated Sodium Channel Blockade

Lidocaine binds to voltage-gated sodium channels and inhibits the movement of sodium ions required for normal nerve impulse propagation.

By interfering with this process, lidocaine temporarily reduces the transmission of sensory signals.

The resulting local anesthetic effect can reduce sensitivity to painful stimuli in the affected area.

Temporary and Reversible Action

Lidocaine's local anesthetic effects are temporary.

Normal sensory transmission gradually returns as the concentration of active anesthetic at the relevant nerve structures decreases.

The onset, intensity, and duration of topical anesthesia depend on the formulation, skin condition, exposure conditions, and individual physiological factors.

These mechanisms describe established lidocaine pharmacology. They do not establish a guaranteed onset time, duration of numbness, or equivalent response in every individual using NEO-CAIN CREAM.

Available NEO-CAIN CREAM Variants

NEO-CAIN CREAM is available in two packaging sizes: 500g and 30g.

Both presentations contain 10.56% lidocaine and share the same declared principal ingredient. Their primary difference is the quantity of cream and the type of container.

NEO-CAIN CREAM 500g

NEO-CAIN CREAM 500g is the larger packaging presentation within the product range.

It contains 500g of topical anesthetic cream with a declared lidocaine concentration of 10.56%.

The product is supplied in a wide-mouth jar designed for professional supply environments where a larger quantity of cream is required.

The 500g packaging format does not change the active ingredient concentration or permit larger patient exposure than the applicable product instructions allow.

NEO-CAIN CREAM 30g

NEO-CAIN CREAM 30g is the compact tube presentation of the same lidocaine-based product.

Each tube contains 30g of cream formulated with 10.56% lidocaine.

The smaller container provides a portable packaging option and may be appropriate for professional settings that require lower overall inventory quantities.

The 30g tube contains the same declared active ingredient concentration as the 500g jar.

The 500g and 30g presentations are distinguished by net weight and container type, not by a different lidocaine concentration. The total package weight must not be confused with an appropriate amount for a single application.

NEO-CAIN vs. NEO-PRO CREAM

NEOGENESIS markets more than one topical anesthetic cream. NEO-CAIN and NEO-PRO are distinct products with different active ingredient compositions.

NEO-CAIN is the lidocaine-only product, while NEO-PRO uses a combination of lidocaine and prilocaine.

The products should be evaluated according to their individual compositions, contraindications, and applicable regulatory labeling.

Different active ingredient combinations and percentages do not establish a simple ranking of clinical potency, duration, or safety between topical anesthetic formulations.

Packaging & Product Presentation

NEO-CAIN CREAM is supplied in two manufacturer-documented packaging formats: a 500g jar and a 30g tube.

Buyers should verify the original manufacturer label, net weight, lidocaine concentration, lot number, expiration date, and any market-specific regulatory markings.

NEOGENESIS describes an ICS authentication feature on selected NEO-CAIN jar packaging. The presence and format of authentication features should be verified against the actual supplied product.

Packaging appearance and labeling may vary by manufacturing batch or destination market. The correct product should be identified using its complete name, active ingredient concentration, and original manufacturer documentation.

Storage & Handling

Published NEO-CAIN product information specifies storage at room temperature between 1°C and 30°C in a tightly closed container.

The original manufacturer labeling should be followed for the specific supplied product.

• Storage Temperature: Store at 1°C to 30°C according to published product specifications.
• Container Closure: Keep the jar or tube securely closed when not in use.
• Original Packaging: Maintain the product in its original labeled container.
• Product Integrity: Inspect the product for changes in appearance, damaged packaging, or other signs of compromised quality.
• Traceability: Verify the lot number, expiration date, original manufacturer information, and applicable regulatory labeling.

The product should be kept out of the reach of children. The original label determines its expiration date and any additional storage restrictions.

Storage conditions do not establish product safety after contamination, inappropriate exposure, or use beyond the labeled expiration date.

Safety & Regulatory Considerations

NEO-CAIN CREAM contains a high concentration of lidocaine. Its use requires particular attention to total exposure, skin condition, individual sensitivity, and the applicable regulatory instructions.

Systemic Lidocaine Absorption

Lidocaine can be absorbed into the bloodstream following topical application.

Excessive systemic exposure may cause serious adverse effects involving the central nervous and cardiovascular systems.

Symptoms associated with systemic local anesthetic toxicity can include dizziness, confusion, tremors, seizures, abnormal heart rhythm, and breathing difficulties.

The risk of excessive absorption may increase when high-concentration anesthetic creams are used over large skin areas, on damaged or irritated skin, for prolonged periods, or under occlusive coverings.

Potential Local Adverse Reactions

Potential local reactions include redness, irritation, itching, burning sensations, and contact hypersensitivity.

Individuals with known hypersensitivity to lidocaine, other amide-type local anesthetics, or relevant excipients may have contraindications to use.

Professional Assessment

Conditions affecting hepatic function, cardiac conduction, or sensitivity to local anesthetics may require additional medical assessment.

Concomitant use of other lidocaine-containing products can increase total exposure and should be considered when evaluating product safety.

NEO-CAIN CREAM is intended for external use only. Contact with the eyes and unauthorized application to mucous membranes or damaged skin should be avoided.

United States Regulatory Considerations

The United States FDA has warned about serious risks associated with high-concentration lidocaine products marketed for cosmetic procedures.

The 10.56% lidocaine concentration in NEO-CAIN exceeds the concentration range permitted under the relevant US nonprescription external analgesic monograph.

US FDA approval for NEO-CAIN CREAM has not been established. The product must not be assumed eligible for unrestricted over-the-counter sale or importation in the United States.

Professional buyers should verify the product's current authorization status, permitted indications, import eligibility, and applicable distribution restrictions in their destination country.

This description is intended for professional product identification and commercial evaluation. It does not provide application quantities, anesthesia protocols, or patient-specific medical instructions. Use must comply with the original product labeling and applicable laws.

Frequently Asked Questions